Passionate about creating a world where people with haemophilia lead fulfilling, self-determined livesSobi is working to develop the next generation of haemophilia treatments.

“Our hope is that in developing these potential treatments we will be able to provide an option with the possibility to further improve protection from bleeding episodes, without increasing the treatment burden for people with haemophilia”, said Dr. Roald van der Laan
Medical Science Manager, Belgium – Netherlands – Luxembourg.

Sobi understands that quality and purity are at the heart of haemophilia therapies. Sobi has been manufacturing recombinant factor VIII for well over a decade. And is now working with Biogen to develop the next generation of haemophilia treatments.

The company has a history of innovation in haemophilia treatments that stretches back more than 50 years. Through his work in haemophilia research at Sobi, Principal Scientist Peter Lind has contributed to one of the major transformational stages in haemophilia treatment: bringing recombinant treatments to people with haemophilia. In the 1980s he established the principles for the design of B-domain deleted factor VIII products. Sobi has been a producer of these products since the 1990s.

Sobi’s mission is to improve the lives of people with haemophilia and other rare diseases. This commitment drives the company towards innovations in the treatment of haemophilia with the simple goal of providing people with haemophilia choices that help them to live the lives they wish for.

Sobi wants to help close the treatment access gap

Sobi believes that providing access to safe, effective and reliable treatment is a shared societal responsibility. Globally, around 75% of people with haemophilia don’t receive regular treatment. Sobi and Biogen have pledged to donate one billion International Units (IU) of clotting factor to humanitarian aid programmes in developing countries over the next 10 years. For the first five years, 500 million IU will support the World Federation of Haemophilia (WFH) Humanitarian Aid Program. This will enable thousands of people in developing countries to access modern treatment over the coming years.

Sobi is co-creating the future

“By working with all members of the community, we aim to support the best possible life-long outcomes for people with haemophilia”, says Geoffrey McDonough, MD, President and CEO of Sobi.

Sobi partners with and supports many haemophilia organisations around the world. By listening to the needs of societies, and seeking to help them achieve their objectives, Sobi aims to become a trusted partner for the long term.

Sobi is an international specialty healthcare company dedicated to rare diseases. There are approximately 7,000 recognised rare diseases, the majority of which are without treatment. Sobi’s mission is to develop and deliver innovative therapies and services to improve the lives of these patients.

© Copyright 2017 - Belgian Society on Thrombosis and Haemostasis - All rights reserved.